USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: AVANIR PHARMACEUTICALS
City: SAN DIEGO
State: CA
Zip+4: 92121 0134
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (858) 622-5215

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,050,263.00 5
SBIR Phase II $1,008,843.00 1

Award List:

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Laura E. Pope
Award Amount: $100,000.00

DOCOSANOL AND ACYCLOVIR FOR TREATING GENITAL HERPES

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Laura E. Pope
Award Amount: $0.00
Abstract:
DESCRIPTION (Provided by applicant): There is a substantial need for a safe, effective topical treatment for genital herpes simplex (HSV) disease. The proposed research aims to evaluate feasibility of continued development of docosanol as a topical treatment for… More

DOCOSANOL AND ACYCLOVIR FOR TREATING GENITAL HERPES

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Laura E. Pope
Award Amount: $1,008,843.00
Abstract:
DESCRIPTION (Provided by applicant): There is a substantial need for a safe, effective topical treatment for genital herpes simplex (HSV) disease. The proposed research aims to evaluate feasibility of continued development of docosanol as a topical treatment for… More

Diverse Neutralizing Human Monoclonal Antibodies to CMV

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Phillip R. Morrow
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this proposal (Phase I and II) is to develop a human monoclonal antibody-based preparation for use in treating CMV infections or transmission. Commercial applications for human monoclonal antibodies are extensive. Phase I specific aims… More

Diverse mix of Human MoAbs to treat Anthrax exposure

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Phillip R. Morrow
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by the applicant): The long-term goal of this proposal (phase I and II) is the development of a human monoclonal antibody-based preparation for use in treating B. anthracis (anthrax) exposure or for use prophylactically. This preparation would most likely be composed of… More

Human Antibodies for Exposure/Protection from Anthrax

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Angray S. Kang
Award Amount: $750,263.00
Abstract:
DESCRIPTION (provided by applicant): Avanir Pharmaceuticals Inc., has developed a powerful platform for the rapid generation of high affinity fully human monoclonal antibodies that can be selected on their ability to neutralize anthrax toxin PA as exemplified by our lead candidate 8C1 (Kd 1.2… More